Durvalumab, a human monoclonal antibody targeting the programmed death-ligand 1 (PD-L1) protein, has recently been granted the United States Food and Drug Administration (US FDA) approval as the first and only immunotherapy for patients with limited-stage small-cell lung cancer (LS-SCLC) who have not experienced disease progression following concurrent platinum-based chemotherapy and radiation therapy.¹ This approval, based on results from the phase 3 ADRIATIC trial, marks a significant milestone in the treatment of this aggressive form of lung cancer, offering new hope for improved survival outcomes.¹

Polyunsaturated fatty acids (PUFAs) have been postulated to impact cancer incidence and survival, but epidemiological evidence remains inconclusive.1 In a population-based cohort study, extensive data from the United Kingdom (UK) Biobank was used to investigate the association between plasma levels

Enzalutamide, a novel hormonal therapy (NHT), in combination with androgen deprivation therapy (ADT), has emerged as one of the novel treatment options for metastatic hormone-sensitive prostate cancer (mHSPC).1 The latest guidelines from the American Society of Clinical Oncology (ASCO) recommend the